Barinthus Biotherapeutics plc.
Barinthus Biotherapeutics plc. (BRNS): 9 pipeline candidates · ~61 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
61.3 months
D/E 0.39 · 0% dilution
Lead: Phase 2
9 candidates
N/A
N/A
A transparent, data-derived signal for Barinthus Biotherapeutics plc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$26.6M
Cash
$67.2M
Quarterly Burn
$3.4M
Runway
61.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
9
Total value held
$6.1M
| Holder | Shares | Value |
|---|---|---|
| m&g plc | 5,197,349 | $5.2M |
| glr partners, llc | 1,243,377 | $707K |
| renaissance technologies llc | 151,000 | $86K |
| citadel advisors llc | 118,996 | $68K |
| gts securities llc | 73,210 | $42K |
| hightower advisors, llc | 37,450 | $21K |
| rhumbline advisers | 11,685 | $7K |
| geode capital management, llc | 11,568 | $7K |
| morgan stanley | 2,210 | $1K |
Frequently asked questions
How many drug candidates are in Barinthus Biotherapeutics plc.'s pipeline?
Barinthus Biotherapeutics plc. (BRNS) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Barinthus Biotherapeutics plc.'s lead drug candidate?
Barinthus Biotherapeutics plc.'s most advanced tracked candidate is chadox1-hbv (Phase 2) for Chronic Hepatitis B.
What is Barinthus Biotherapeutics plc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Barinthus Biotherapeutics plc. has approximately 61.3 months of cash runway.
What is Barinthus Biotherapeutics plc.'s market capitalization?
Barinthus Biotherapeutics plc.'s market capitalization is approximately $26.6M.
Who is the CEO of Barinthus Biotherapeutics plc.?
Mr. William James Enright MBA is the chief executive officer of Barinthus Biotherapeutics plc. (BRNS).
Get the full picture on Barinthus Biotherapeutics plc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.